Evidence brief · Supplement

Akkermansia muciniphila for Insulin sensitivity / metabolic markers

Evidence grade C — One key trial

Overall grade
Grade C
Last revised
1
graded outcome
0
references listed

Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.

1 at grade C — 1 graded row

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Insulin sensitivity / metabolic markersEvidence grade C

    One key trial

    Smalllow

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Thin evidence: Insulin sensitivity / metabolic markers (grade C).

The evidence in words

The verdict

For insulin sensitivity / metabolic markers, Akkermansia muciniphila earns evidence grade C (small effect, low consistency) — the evidence is limited or mixed. One key trial

How it might work

It strengthens the gut mucus barrier and signals to improve insulin sensitivity and reduce metabolic inflammation.

How to use it

Safety & cautions

Well tolerated in the trial; long-term safety of a novel single-strain probiotic is not established.

Bottom line

A genuinely exciting 'next-gen' probiotic with one supportive metabolic trial — worth watching, not yet a proven staple. The pasteurized form is the studied one.

Goes with

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.

Last revised . A grade is this entry's reading of the evidence, not medical advice.